Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease

Fig. 2

The distribution pattern of plasma amyloid-β oligomers determined using the Multimer Detection System (MDS) in patients with Alzheimer’s disease (AD) and cognitively normal control subjects (NC). The MDS relative luminescence units (RLUs) were higher in the AD group than in the NC group (p < 0.0001). The horizontal bar is the median MDS RLU. However, there was an overlap between the two groups, suggesting that further optimization of the MDS is required

Back to article page